USP14 and neoplasm: This notion is confirmed using the MC38 syngeneic mouse model, which shows that both USP14 knockdown and an inhibitor restrain tumor growth, increase the infiltration of cytotoxic T cells, decrease the infiltration of Tregs, and finally promote the response to anti-PD-1 therapy.